Drug Delivery

A nanofluidic device, smaller than a grain of rice, aims to deliver localized immunotherapy without side effects.

A company looks to give the humble injection an inventive makeover.

Next-generation pain medications could improve on current opioid offerings.

With big pharma seemingly pulling out of the field, what hope remains for novel treatments for Alzheimer’s disease?

Why we shouldn’t forget gelatin’s longstanding reputation as a reliable and trusted excipient.

The end of “mini me” medicine is over, says Andrew Parker, because we can do better when it comes to pediatric care.

As we meet increasing demand and satisfy trends towards self-administration in the injectables market, patient safety must remain the primary driver for innovation.

Products are becoming increasingly complex and we need to get better at recognizing the strategies with the best advantages.

Antibody drug conjugates have not yet lived up to their potential, but there is hope – if we turn to the right solutions and techniques.

Rare diseases aren’t the only field that can benefit from repurposing – the eye is also often overlooked.